Longitudinal study of intravenous versus subcutaneous immunoglobulin replacement therapy in hematological malignancy
Rattachement africain : au. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
AIM: To present findings from a longitudinal study on infection risk, mortality, and patient perspective of intravenous immunoglobulin (IVIg) and subcutaneous immunoglobulin (SCIg) treatment for patients with hypogammaglobulinemia secondary to hematological malignancy or its treatment (abbreviated as SID). METHODS: Observational study period included final year of IVIg (13 patients) and of the first 3 years of SCIg (17 patients) with SID. Data were collected on clinical outcomes from medical records and patient perception via study specific questionnaire. RESULTS: The median age was 63 years (53-76 years), and for 82.4% of patients their hematological malignancy was in complete remission. The annual mean serum IgG trough levels remained stable over the 4 years and were 7.0 g/L (±2.77 g/L) with IVIg, and 8.0 g/L (±1.75 g/L), 8.7 g/L (±2.75 g/L), and 7.6 g/L (±2.89 g/L) (year 1, 2, and 3, respectively) with SCIg. While the annual infection rate was similar, the rate of hospitalization due to infection fluctuated, with 37%, 9%, 15%, and 32% in year 1, 2, 3, and 4 respectively. There were no systemic adverse events with IVIg or SCIg. Patients reported a strong preference for SCIg. One patient died due to progression of underlying disease and infection within the study period. CONCLUSION: SCIg was the preferred treatment mode over IVIg in our cohort, but both were well tolerated without any systemic adverse events in 4-year follow up. The dosage and serum IgG levels were stable throughout. However, the number of infections requiring hospitalization fluctuated. It is anticipated that these findings encourage more hospitals to offer SCIg for SID patients.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- Longitudinal study of intravenous versus subcutaneous immunoglobulin replacement therapy in hematological malignancy
- Date Crossref
- 18/01/2021
- Éditeur
- Wiley
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
University of the Sunshine Coast pays non établi dans la noticeUniversité ou école supérieure
-
Sunshine Coast University Hospital pays non établi dans la noticeÉtablissement de santé
-
Griffith University Menzies Health Institute Queensland pays non établi dans la noticeUniversité ou école supérieure
-
School of Health and Behavioural Sciences pays non établi dans la noticeUniversité ou école supérieure
-
Quality and Innovation Unit Sunshine Coast Hospital and Health Service Sunshine Coast Queensland Australia Safety pays non établi dans la noticeÉtablissement de santé
-
Department of Cancer Care Sunshine Coast Hospital and Health Service Sunshine Coast Queensland Australia pays non établi dans la noticeÉtablissement de santé
-
Department of Immunology Sunshine Coast Hospital and Health Service Sunshine Coast Queensland Australia pays non établi dans la noticeÉtablissement de santé
University of the Sunshine Coast, Sunshine Coast University Hospital et Menzies Health Institute Queensland — Griffith University, avec 4 autres affiliations.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.